Log in

NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Forecast & News

$5.38
+0.20 (+3.86 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$5.18
Now: $5.38
$5.38
50-Day Range
$4.36
MA: $5.08
$5.76
52-Week Range
$2.32
Now: $5.38
$6.05
Volume102,162 shs
Average Volume141,218 shs
Market Capitalization$95.42 million
P/E Ratio6.56
Dividend YieldN/A
Beta1.42
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
CUSIPN/A
Phone844-967-2633

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.70 million
Cash Flow$0.84 per share
Book Value$0.97 per share

Profitability

Net Income$-14,350,000.00
Net Margins-297.30%

Miscellaneous

EmployeesN/A
Market Cap$95.42 million
Next Earnings Date4/8/2020 (Estimated)
OptionableOptionable

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.


5G Flaw Exposed: $5 Stock Holds Key To $12 Trillion Opportunity (Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Thursday, January, 9th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11. The biotechnology company had revenue of $0.67 million for the quarter. Oramed Pharmaceuticals had a negative return on equity of 38.51% and a negative net margin of 297.30%. View Oramed Pharmaceuticals' Earnings History.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Oramed Pharmaceuticals.

What price target have analysts set for ORMP?

2 equities research analysts have issued 1 year price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Oramed Pharmaceuticals' stock price to reach $13.50 in the next year. This suggests a possible upside of 150.9% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

What is the consensus analysts' recommendation for Oramed Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

Has Oramed Pharmaceuticals been receiving favorable news coverage?

News stories about ORMP stock have trended negative on Saturday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Oramed Pharmaceuticals.

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 448,700 shares, a decline of 23.5% from the December 15th total of 586,300 shares. Based on an average trading volume of 210,900 shares, the days-to-cover ratio is currently 2.1 days. Currently, 3.4% of the company's stock are sold short. View Oramed Pharmaceuticals' Current Options Chain.

Who are some of Oramed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oramed Pharmaceuticals own?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:
  • Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
  • Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
  • Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $5.38.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $95.42 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is http://www.oramed.com/.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]


MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel